BioMarin Pharmaceutical has acquired ZyStor Therapeutics, a privately held US biotechnology company developing enzyme replacement therapies (ERTs) for the treatment of lysosomal storage disorders. ZyStor's lead product candidate, ZC-701 for the treatment of Pompe disease, is slated to enter the clinic next year.
Under the agreement, BioMarin bought ZyStor for $22 million up front and up to an additional $93 million if certain...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?